Formulation for a probiotic stable at baking temperatures and encapsulation of the probiotic to ensure the life of same in shelf-stable foods and the viability thereof in consumption

A scalable spray drying encapsulation process using a carbohydrate-protein hybrid solid nanoparticle stabilizes probiotics at high temperatures, addressing heat sensitivity and ensuring their viability and stability, thus enhancing their health benefits in baked goods.

WO2024228613A1PCT designated stage expired Publication Date: 2024-11-07GRUPO BIMBO B DE C V
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/MX2023/050031
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-04
Filing Date
2023-06-06
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

Probiotics are sensitive to heat, leading to significant losses during baking processes and storage, and must survive acidic conditions and reach the intestine viable to exert their health benefits, which existing technologies struggle to achieve effectively.

Method used

The development of a scalable spray drying encapsulation process using a carbohydrate-protein hybrid solid nanoparticle to stabilize probiotics at high temperatures, ensuring their viability and stability during baking and gastrointestinal passage.

Benefits of technology

The process effectively preserves probiotic viability at baking temperatures, maintains stability during storage, and ensures the probiotics reach the intestine alive, enhancing their health benefits without altering the sensory properties or shelf life of baked goods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure MX2023050031_07112024_PF_FP_ABST
    Figure MX2023050031_07112024_PF_FP_ABST
Patent Text Reader

Abstract

Described is an invention for scalable and affordable encapsulation that allows probiotics to survive baking processes, minimising as far as possible the overaddition needed to achieve the CFUs necessary for the corresponding declaration.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Formulation of a stable probiotic at baking temperatures and encapsulation to ensure its shelf life until it is viable for consumption.

[0002] FIELD OF INVENTION

[0003] The global market for functional foods is expanding daily, driven by growing consumer demand and a growing awareness of including healthy foods that offer health benefits in their daily diets.

[0004] The global functional products market is valued at $139.2 billion, equivalent to 5% of the global market value in Mexico, with a steady annual growth rate of 3.9%. The global probiotics market represents $52.9 billion, while in Mexico, it is valued at $0.04 billion, with an annual growth rate of 7%.

[0005] However, North America, especially the United States, has seen accelerated growth in this market, with 3% of new food and beverage products containing probiotics.

[0006] BACKGROUND OF THE INVENTION

[0007] Probiotics are often found in dairy products, but are increasingly being incorporated into other foods, such as juices, cereals, bars, etc. Most probiotics are heat-sensitive, so their survival during thermal processing is a major obstacle. The heat generated in baking processes can cause significant losses during bread processing and storage. Furthermore, probiotics must survive and grow within the host to exert their beneficial health effects. They must be metabolically stable and active, survive the acidic conditions of the stomach, and reach the intestine in optimal quantities. Likewise, factors such as pH, oxygen content, temperature, and humidity in the product must be optimal to not affect their growth and survival.

[0008] The encapsulation of nutraceuticals, including probiotics, is a strategy that allows a functional ingredient to be made stable under specific conditions. This technology solves some problems in the process because it captures the main ingredient as a central core and coats it with an inert or protective layer that improves stability during passage through the gastrointestinal tract. In the case of probiotics for use in baked goods, it is necessary to maintain their viability at baking temperatures. It is also advisable to stabilize them so that they can reach the human intestine in a viable state, where they can exert their beneficial effects on health.

[0009] Currently, encapsulation is an important alternative for the implementation of probiotics in foods, to allow them to reach the site where they will exert their action alive, protecting them from environmental conditions (heat, light, air, humidity).

[0010] There are different methods for encapsulating bioactive compounds, such as emulsion, liposome formation, electrospinning, and spray drying. Most of them involve the use of solvents or technologies that are difficult to scale in the industry (Ayala-Fuentes et al., 2021). However, spray drying is an industrially scalable technique, fast, with low operating costs, and that does not require the use of solvents and does not generate pollutants. Therefore, it is defined as sustainable.

[0011] Patent Application MX / a / 2016 / 006536; Process for the production and formulation of acidified fermented beverages based on strains of Lactobacillus paracasei tolerans pfthl-10 and pfthl-22 with probiotic activity, from Agave atrovirens juices and honeys. This document describes the process for transforming agave honeys or syrups and saps from two different bacterial cultures belonging to the species Lactobacillus paracasei tolerans. The aforementioned microorganisms have probiotic activity in vitro, as they produce bacteriocins and organic acids produced in the fermentation of honeys and agave juices; which translates into the inhibition of the growth of pathogenic and toxigenic enterobacteria. During fermentation, the bacterial strains object of the invention rapidly consume the monosaccharides and some oligosaccharides that are available, while secreting pleasant flavors and aromas.At the end of a fermentation process lasting between 48 and 120 hours, followed by a product stabilization period at refrigeration temperature for 2 to 21 days, an acidulated beverage is obtained that contains the probiotic microorganisms themselves, as well as polymerized oligofructans and fructans. This product does not contain alcohol, has a very low glycemic sugar content, and is free of animal fats, cholesterol, or allergens derived from milk proteins. It is therefore a functional beverage that contains probiotic microorganisms, prebiotic oligosaccharides, and short-chain organic acids.

[0012] Unlike the present invention, this document does not mention high temperatures to preserve the properties of a probiotic. The process of transforming honey or syrups and agave sap from two different bacterial cultures belonging to the Lactobacillus species cannot be extrapolated in any way to the process we have because this is a fermentation process and has nothing to do with heat or drying of the bacteria.

[0013] International Application MX / a / 2014 / 012235; Use of lactic acid bacteria to prepare fermented food products with increased natural sweetness.

[0014] This document describes the provision of an alternative to adding sweeteners to fermented milk products to achieve the desired sweet taste without the added calories. Furthermore, it would be highly advantageous to establish a method for reducing lactose in fermented milk products to a level acceptable to consumers with lactose intolerance. The aforementioned problems were solved by providing mutant strains of Streptococcus thermophilus and mutant strains of Lactobacillus delbrueckii subspecies bulgaricus that excrete glucose into milk when the milk is inoculated and fermented with such strains of Streptococcus thermophilus and Lactobacillus delbrueckii subspecies bulgaricus.Thus, the present invention relates to strains of Streptococcus thermophilus and Lactobacillus delbrueckii subspecies bulgaricus which secrete glucose into the dairy substrate during fermentation, as well as to mixed cultures comprising the strains of Streptococcus thermophilus and the strains of Lactobacillus delbrueckii subspecies bulgaricus, to starter cultures comprising the strains, and to dairy products made from the cultures. The present method also relates to the use of the strains for decreasing the lactose content of a fermented food product and for enhancing the growth of the probiotic BB-12(r).

[0015] This document does not mention high temperatures to preserve the properties of a probiotic. This is a fermentation process. Our process does not involve fermentation of raw materials, nor do we use fermented products for their desired sweet taste without added calories. This technology does not affect the taste of the final product.

[0016] Publication: KR2021181788A; Title: A non-stop production process to improve freeze-dry survival, heat tolerance, storage stability, and digestive stability of probiotics using spontaneous matrix encapsulation technique.

[0017] This document describes a method for preparing alginate-hydrogel encapsulated probiotics, which involves (a) culturing probiotics in a medium containing alginic acid salts and salts to form hydrogels combining with alginic acid to spontaneously generate alginate-hydrogels simultaneously with probiotic proliferation, and (b) recovering the encapsulated probiotics from the spontaneously produced alginate hydrogel. The encapsulated probiotics are encapsulated in an alginate hydrogel, the encapsulated probiotics being of the matrix type. The medium of step (a) further comprises an encapsulation enhancer wherein the encapsulation enhancer is chosen from starch, crystalline cellulose, chitosan, carboxymethylcellulose (CMC), and skim milk powder. Probiotics are Lactobacillus sp., Bifidobacterium sp., Streptococcus sp., Lactococcus sp., Enterococcus sp., Leuconostoc sp., Pediococcus sp. and Weissella sp.

[0018] Composition: The salt of alginic acid is 0.1-40 g / L, and the salt for forming a hydrogel by binding with alginic acid is contained in the medium in 0.5-10 g / L. The encapsulation enhancer is contained in the medium in an amount of 1-20 g / L. Preferred method: Step (a) involves dissociating the cation of the salt that binds to alginic acid to form a hydrogel by the acid generated by the cultivation of the probiotics, and spontaneous binding of the dissociated cation and alginic acid. The method further involves (c) lyophilizing the encapsulated probiotics with the recovered alginate hydrogel.

[0019] This document in particular mentions an encapsulation where the encapsulation enhancer is chosen from starch, which may be relevant for a heat-stable stabilized probiotic.

[0020] This particular document does mention temperatures and their tolerance. However, the present invention does not use a hydrogel composed of alginate and a complex carbohydrate. The present invention uses a hybrid solid carbohydrate-protein nanoparticle. The formulation differs in the type of encapsulant and, therefore, its application. Ours is for use in food, and all its ingredients are suitable for use in food, especially in baked goods.

[0021] Publication: KR2006130968A; Title: Probiotic Bifidobacterium Bourn R5 strain with excellent acid tolerance, bile acid tolerance, oxygen tolerance, and heat stability and probiotic composition comprising the same or its culture medium.

[0022] This document describes a probiotic Bifidobacterium bourn R5 strain and a probiotic composition comprising the same strain are provided to inhibit the growth of various intestinal pathogenic bacteria effectively, and improve acid tolerance, bile acid tolerance, oxygen tolerance and heat stability of the strain.

[0023] The probiotic Bifidobacterium bourn R5 strain (KCCM 10669P) capable of inhibiting the growth of intestinal pathogenic bacteria is provided, where the Bifidobacterium bourn R5 strain (KCCM 10669P) is isolated from the contents in the first stomach of a cow; and the intestinal pathogen bacteria is Salmonella gallinarum, Salmonella enteritidis, Salmonella typhimurium, Staphylococcus aureus, enterotoxigenic Escherichia coli, Listeria monocytogenes, Campylobacter jejuni or Clostridium perfringens. The probiotic has a composition comprising the probiotic Bifidobacterium bourn R5 strain (KCCM 10669P) and its culture medium, where the composition is used as a feed additive. The composition is heat-dried or freeze-dried, and the amount of probiotic Bifidobacterium boumR5 strain (KCCM10669P) is 105 to 1012 cfu / g based on the total weight of the composition.

[0024] This document deals with an isolated and modified strain. However, in the present invention, no strain is used and we do not modify the strains themselves; it is a coating material.

[0025] Publication: KR201696641 A, Title: Lactobacillus fermentum PL9119 with biofunctional activities and high heat stability as a probiotic without antibiotic resistance. This document describes a novel Lactobacillus fermentum PL9119 strain used in composition for intestinal disorders, and used in health and functional foods such as milk, yogurt, soy milk, meat products, sausage, bread, beverages, capsules or stick packs. The Lactobacillus fermentum PL9119 strain comprises a 16S rRNA nucleotide sequence having 648 nucleobases, given in the specification, where Lactobacillus fermentum strain PL9119 is deposited in Korean Collection for Type Cultures (KCTC 13038BP).The strain is selected from the group consisting of strains resistant to ampicillin, gentamicin, erythromycin, clindamycin, tetracycline, chloramphenicol, vancomycin, synercid, quinupristin, Ifo pristi nao or a combination, where the antibiotic agent is not resistant to the group of linezolid or rifampicin, which is free from the risk of resistance metastasis. The strain or culture solution in the prophylactic composition is excellent in acid resistance and bile resistance.The strain is selected from the group consisting of Escherichia coli O157:H7 strain held at American Type Culture Collection (ATCC No: 43894), Salmonella typhimurium held at Canadian Centre for Agri-Food Research in Health and Medicine (CCARM No: 8001), Salmonella enteritidis held at Canadian Centre for Agri-Food Research in Health and Medicine (CCARM No: 8010), Enterococcus thecalis held at American Type Culture Collection (ATCC No: 29212), Staphylococcus aureus held at Canadian Centre for Agri-Food Research in Health and Medicine (CCARM No: 0045) and Listeria monocytogenes held at American Type Culture Collection (ATCC No: 19113C3a). The functional health food promotes intestinal health activity through inhibition of food poisoning bacterial growth and lipase production.

[0026] Unlike what is described in the present invention, this strain is not used and the strains themselves are not modified; it is a coating material.

[0027] Publication: BR1120133284A; Title: Process for preparing heat- and moisture-resistant probiotic bacteria in the form of stabilized probiotic granules for a liquid-based food product; process for preparing a liquid-based food product; stabilized probiotic granules for mixing into a liquid-based food product; and a food product.

[0028] This document provides healthy thermally processed or heat-processable food products that beneficially affect the consumer's intestinal microbial balance.

[0029] Food products are particularly liquid-based products that comprise a probiotic component capable of withstanding heat and humidity.

[0030] The process (I) for preparing heat and moisture resistant probiotic bacteria in the form of stabilized probiotic granules for a liquid-based food product comprises: (i) preparing core granules containing probiotic bacteria, substrate and optionally other food grade ingredients; (ii) optionally coating the core granules with an inner layer to obtain sealed core granules (A); (iii) optionally coating (A) with an outer layer comprising a thermosensitive gel-forming polymer to obtain protected core granules (B); and optionally (iv) coating (B) by outer layer comprising a water-soluble polymer.

[0031] The granules comprise a core of probiotic bacteria in a substrate or mixed with a substrate, and at least an inner layer, an outer layer, or an outer layer comprising a water-soluble polymer or an erodible polymer. The substrate comprises a component comprising a bacterial supplement, stabilizer, filler, and / or binder; or a prebiotic saccharide.

[0032] This document deals with a coating gel, the formation process is different because it is liquid-based, the size of the final result is different; ours reaches up to only 4 microns.

[0033] BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 shows the spray drying scheme. The main parts that make up spray drying equipment are a container where the solution to be spray dried is located. In the drying chamber are the atomizing nozzle where the solution is sprayed. Very close to this nozzle there is an outlet for hot air that dries the small droplets formed from the solution. Finally, in the drying chamber, the dry product is obtained, generally with a particle diameter similar to the opening of the atomizing nozzle.

[0035] Figure 2 shows the morphology of the probiotics used. On the left, Bacillus clausii, a sporulated, circular microorganism less than 1 micrometer in size, is very small compared to the second microorganism used. On the right, Lactobacillus acidophilus, the second microorganism used, is significantly larger, rod-shaped, and has an average size of 2 micrometers.

[0036] Figure 3 shows the encapsulation optimization of Bacillus clausii. The optimal concentration was determined at 35% inulin, 60% pea protein, 5% maltodextrin, and an initial probiotic concentration of 4x1011 CFU.

[0037] Figure 4 shows the encapsulation optimization of Lactobacillus acidophilus. The optimal concentration was determined at 30% inulin, 40% pea protein, 25% maltodextrin, and an initial probiotic concentration of 4x108 CFU.

[0038] Figure 5. Optimal formulations for probiotics. These formulations were obtained through two experimental designs using spray separation technology. The integration of the two experimental designs served as the basis for achieving an optimal formulation, and a proposal for a formulation combining both probiotics in a single microencapsulation.

[0039] In Figure 6 are presented images of the morphology of the microencapsulates obtained by Scanning Electron Microscopy (SEM). Scanning Electron Microscopy (SEM) of microencapsulates obtained, a) The encapsulation of Basillus clausii 3.53x1010 CFU / g of encapsulate is observed, b) the encapsulation of Lactobacillus acidophilus 1.22x108 CFU / g of encapsulate is observed, and in c) the encapsulation of 2 probiotics containing Lactobacillus acidophilus in 6.69X108 CFU / g of encapsulate and Basillus clausii in 2.24X101 OCFU / g of encapsulate.

[0040] Figure 7 shows the scaling of microencapsulation production. The process was scaled from a 500 mL solution, where 4 to 5 were obtained, to a 5 L process, where approximately 150 g of each microencapsulation were obtained per run.

[0041] Figure 8 shows the microbread prototypes with encapsulations generated using the direct method. From left to right, the control bread, the microencapsulated bread from Spain (positive control), the encapsulated bread with L. acidophilus, the encapsulated bread with B. clausii, and the encapsulated bread with the two probiotics (L. acidophilus and B. clausii) are shown.

[0042] Figure 9. 460g bread prototypes with encapsulations generated by the sponge method. From left to right, the bread with the two probiotics (L. acidophilus and B. clausii), the bread with microencapsulated B. clausii, the bread with microencapsulated L. acidophilus, and finally the control bread.

[0043] Figure 10 describes the in vitro digestion process.

[0044] DETAILED DESCRIPTION OF PREFERRED MODALITIES

[0045] The encapsulation of nutraceuticals, including probiotics, is a strategy that allows a functional ingredient to be given stability under specific conditions. This technology solves some problems in the process because it captures the main ingredient as a central nucleus and coats it with an inert or protective layer that improves stability during passage through the gastrointestinal tract (Vasishtha, 2005). In the case of probiotics for use in baked goods, it is necessary to maintain their viability at baking temperatures. It is also advisable to stabilize them so that they can reach the human intestine viable, where they can exert their beneficial effects on health. Currently, encapsulation constitutes an important alternative for the implementation of probiotics in foods, allowing them to reach the site where they will exert their action alive, protecting them from environmental conditions.

[0046] There are different methods for encapsulating bioactive compounds, such as emulsion, liposome formation, electrospinning, and spray drying. Most of them involve the use of solvents or technologies that are difficult to scale in the industry (Ayala-Fuentes et al., 2021). However, spray drying is an industrially scalable technique, fast, with low operating costs, and that does not require the use of solvents and does not generate pollutants, therefore, it is defined as sustainable.

[0047] Spray drying is a widely used technology in the food industry for producing powdered ingredients, such as instant coffee and infant formula, among others. The advantages of spray drying are that it is a very robust and scalable technique, and it offers excellent yields. Figure 1 presents a diagram explaining the main components of the technology.

[0048] The main objective was to develop a scalable and affordable encapsulation process that allows probiotics to survive our baking processes, minimizing the over-addition required to achieve the CFUs required to make the corresponding claim.

[0049] The following stages were considered for the implementation of the process:

[0050] 1) Functional Ingredient Development. A Box-Behnken experimental design is used to optimize the formulation, as it reduces the number of runs required. This design also helps validate the microencapsulation of previously reported probiotics to maintain viability at elevated temperatures (170–210° C). Twenty-four experimental runs are required to complete the experimental design and optimize the response variables: size, viability, and loading efficiency.

[0051] 2) Microbreadmaking prototype generation. Evaluate the performance of the optimized formulation in baking, conducting 16 experiments to determine the dosage required to ensure the desired probiotic concentration. Finally, the company plans to produce a commercial-sized loaf for sensory analysis.

[0052] 3) Evaluation of shelf life of developed bread. Test 3 shelf life conditions, considering 3 temperatures. o C, 25° C and 40° C, at relative humidity (60%) to quantify the shelf life of the final product and the viability of the probiotics in CFU / g.

[0053] 4) In vitro digestion evaluation of the developed bread. Evaluate the number of viable microorganisms by performing an in vitro digestion test to determine the number of viable microorganisms that could potentially reach the human intestine.

[0054] STAGE 1: Functional Ingredient Development.

[0055] It was proposed to generate an experimental design (Box-Behnken) which is a rotating spherical response surface, which includes a central point and midpoints between the corners, circumscribed on a sphere, because it reduces the number of runs to optimize the formulation, which helps us validate the microencapsulation of probiotics already reported, to preserve viability at high temperatures (170 o - 210° C). Twenty-four experimental runs must be performed to complete the experimental design and optimize the response variables: Size, viability and loading efficiency.

[0056] First, 3 proofs of concept were carried out to determine that through spray drying it was possible to obtain an encapsulation of 2 probiotics with different morphological characteristics (Figure 2).

[0057] These strains were chosen for their functional properties. Lactobacillus acidophilus has been widely reported to maintain and restore the health of the digestive system microbiota, support the immune system, and inhibit various pathogenic bacteria. As for Bacillus clausii, its properties, in addition to maintaining and restoring the digestive system microbiota and supporting the immune system, have been reported to maintain intestinal permeability, thereby improving nutrient absorption. It also reduces bloating, flatulence, diarrhea, or constipation, and relieves gastrointestinal pain and inflammation.

[0058] Subsequently, 2 experimental designs were carried out for the optimization of 2 probiotics, a spore-forming one -Bacillus clausii- and a lactobacillus -Lactobacillus acidophilus-. In these experimental designs, the concentration of inulin and the vegetable protein used were varied, and the response variable was the viability of the organisms (Table 1 and Table 2).

[0059] Table 1. Experimental design carried out for Bacillus clausii*.

[0060] *The factors that varied were A: % Inulin, and B: % pea protein, the response variable was the viability obtained at the end of spray drying in Colony Forming Units per gram (CFU / g)

[0061] Table 2. Experimental design carried out for Lactobacillus acidophilus*

[0062] *The factors that varied were A: % Inulin, and B: % pea protein, the response variable was the viability obtained at the end of spray drying in Colony Forming Units per gram (CFU / g)

[0063] Both experimental designs were optimized through surface analysis using Design-Expert® software. Optimal conditions were obtained for both experimental designs (Figure 3 and Figure 4). Under these conditions, the optimal formulation for both probiotics was established.

[0064] Figure 3. Optimization of Bacillus clausii encapsulation. The optimal point was determined at 35% inulin and 60% protein. This way, the optimal formulation parameters for each of the microorganisms were obtained, and a formulation was proposed for the encapsulation of both probiotics in a single microencapsulated ingredient obtained by spray drying (Figure 5).

[0065] At this stage, 3 encapsulates with temperature stability characteristics were obtained, with a concentration of microorganisms:

[0066] 1. Basilillus clausii 3.53x1010 CFU / g of encapsulated

[0067] 2. Lactobacillus acidophilus 1.22x108 CFU / g encapsulated

[0068] 3. Encapsulated with 2 probiotics it has Lactobacillus acidophilus at 6.69X108 CFU / g of encapsulated and Basilius clausii at 2.24X1010 CFU / g of encapsulated.

[0069] Figure 6. Scanning electron microscopy (SEM) of the obtained microencapsulation, a) the encapsulation of Basilius clausii 3.53x1010 CFU / g of encapsulation is observed, b) the encapsulation of Lactobacillus acidophilus 1.22x108 CFU / g of encapsulation is observed, and in c) the encapsulation of 2 probiotics containing Lactobacillus acidophilus in 6.69X108 CFU / g of encapsulation and Basillus clausii in 2.24X1010 CFU / g of encapsulation.

[0070] The production of these encapsulants was scaled from equipment that yielded 4 to 5 grams per run (laboratory scale) to one that yielded approximately 150 g per run (pilot scale). The results were identical (Figure 7). This demonstrates that the formulation is robust and can be scaled up to achieve similar viability.

[0071] STAGE 2: Generation of breadmaking prototype by Microbreadmaking.

[0072] This stage aimed to evaluate the performance of the optimized formulation in baking, conducting 16 experiments to determine the dosage required to ensure the desired probiotic concentration. Finally, the goal was to produce a commercial-sized loaf for in-house sensory analysis.

[0073] The three encapsulants were tested in triplicate on sliced ​​bread using the recipe provided by the BIMBO® team at a dosage of 4g / 100g of dry product. The breads were obtained with sensory characteristics identical to those of the control bread (Figure 8) and with microorganism viability at a concentration greater than 1x106 CFU / g, which is required to define a food as probiotic (Table 3).

[0074] Table 3. Results in microbreading tests at doses of 4g / 100g

[0075] * In Spain, the concentration required to be a 1x106 probiotic bread could not be quantified.

[0076] Figure 8. Microbread prototypes with encapsulated ingredients generated by the direct method. From left to right, the control bread, the microencapsulated bread from Spain (positive control), the encapsulated bread with L. acidophilus, the encapsulated bread with B. clausii, and the encapsulated bread with the two probiotics (L. acidophilus and B. clausii) are shown.

[0077] The concentration of microencapsulation per 100g of bread was increased to determine the effective dose. It was concluded that 4g / 100g to 10g / 100g is sufficient to achieve cell viability above 1x106 CFU / g of bread, as suggested by Mexican Standards.

[0078] Table 4. Results in microbreading tests at doses of 10g / 100g Commercial-sized 460g loaves were also made using the sponge method. Differences in loaf volume were observed in these prototypes. However, these differences were attributed to the fermentation times used and the percentage of water added to the recipe (Figure 9).

[0079] These commercial prototypes, along with samples of each microencapsulation sufficient to make commercial breads, were delivered to BIMBO® so they could be tested using its bread-making methodology.

[0080] pH measurements were taken on the prototype bread, and no changes were observed due to the addition of any of the microencapsulated ingredients. Similarly, greater fermentation was observed in the breads with the addition of Lactobacillus acidophilus. It cannot be determined whether this is constant; this is attributed to the encapsulation of the microorganism.

[0081] These microbread and commercial bread tests conclude that the highest concentration of microorganisms is found in the central part of the bread crumb. Furthermore, the dose to obtain a concentration greater than 1x106 CFU / g must be at least 4g / 100g of solid ingredients in the bread, and that concentrations greater than 1x108 CFU / g in the bread crumb can be obtained with up to 10g / 100g of solid ingredients.

[0082] STAGE 3: Evaluation of shelf life of developed bread.

[0083] It was proposed to test three shelf-life conditions, considering three temperatures and one relative humidity to quantify the shelf-life of the final product and the viability of the probiotics in CFU / g.

[0084] The temperatures of 37°C, 20°C and 4°C were tested. oC at a relative humidity of 60% and it was determined that the shelf life of the product, using the preservatives indicated by BIMBO®, has a shelf life of more than 30 days at 37° C and increases to 30 days at 20° C and in 4 o C has been monitored for at least 30 days with no apparent effect on sensory properties, no fungal growth, and a viability greater than 1x108 CFU / g. Shelf life is similar for control breads and breads supplemented with probiotics. Appendix 1 shows the observation tables for each of the temperatures tested.

[0085] STAGE 4: In vitro digestion evaluation of the developed bread.

[0086] It was proposed to evaluate the number of viable microorganisms by performing an in vitro digestion assay to determine the number of viable microorganisms that would potentially reach the human intestine.

[0087] Samples were digested in triplicate. One gram of each sample was subjected to:

[0088] • Digestion with porcine amylase at pH 4 for 20 minutes

[0089] • Digestion with porcine pepsin at pH 2 for 120 minutes

[0090] • Digestion with porcine pancreatin at pH 9.1 for 120 minutes

[0091] After digestion, the cell viability of the samples was measured, obtaining the following results shown in Table 5.

[0092] They observed that the concentration obtained in the bread was sufficient to be declared a probiotic bread. Regarding digestion, no additional protection was observed with the encapsulation provided by Spain's AB-life compared to the encapsulation obtained at the Monterrey Institute of Technology® to protect a Lactobacillus microorganism.

[0093] In the case of the microencapsulates obtained at the Tecnológico de Monterrey®, it is observed that the microorganism that best resisted in-vitro digestion was the sporulated microorganism, although Lactobacillus acidophilus managed to survive at a concentration of 9.0x101 CFU per gram.

[0094] Table 5. Results in microbreading tests at doses of 10g / 100g with in vitro digestion

[0095] The in vitro digestion replicate was performed, and the results are shown in Table 6. As can be seen, the best encapsulation was the double probiotic in a single encapsulation; it performed best not only in baking but also under in vitro digestion conditions.

[0096] Table 6. Results in microbreading tests at doses of 10g / 100g with in-vitro digestion, Replica 1 and 2.

[0097] Optimal formulations for microencapsulation were obtained

[0098] Basillus clausii with 35% Inulin, 60% pea protein, 5% maltodextrin and an initial concentration of probiotics in the order of 4x1011 CFU.

[0099] Lactobacillus acidophilus with 30% inulin, 40% pea protein, 25% maltodextrin and an initial concentration of probiotics in the order of 4x108 CFU.

[0100] Both probiotics with 30% Inulin, 40% pea protein, 25% maltodextrin and an initial concentration of probiotics in the order of 4x1011 CFU for Basillus clausii and 4x108 CFU for Lactobacillus acidophilus.

[0101] These formulations could be scaled up to produce from 4g to 150g per run on spray drying equipment.

[0102] Due to the size of the microorganisms, it is determined that it is possible to change the microorganism to be encapsulated within the size range of those tested, this is due to the size of the encapsulated microorganisms that ranged from circular spore-forming microorganisms (less than one micrometer) to bacilli (approximately 2 micrometers) with the formulations obtained.

[0103] The optimal dosage for incorporation into bread is between 4g and 10g per 100g of dry ingredients for making sliced ​​bread, to obtain a viability of 1x106 to 1x108 for each microorganism.

[0104] It is possible to add it to white bread as well as to whole wheat bread, obtaining sufficient viability of the microorganisms.

[0105] Sliced ​​bread does not change its sensory properties or its shelf life when tested at three different temperatures.

[0106] The formulation that performed best in the baking process and in vitro digestion based on probiotic viability was the double-probiotic encapsulated formulation. In vitro digestion results.

[0107] In-vito digestion 1 gram sample.

[0108] In-vito digestion 1 gram sample.

Claims

CLAIMS 1. The formulation of a probiotic stable at baking temperatures encapsulated for food, the formulation consists of: a Bacillus clausii probiotic, where 35% inulin, 60% by microencapsulation is obtained by spray dryer, where the Basillus clausii probiotic with 35% Inulin, 60% pea protein, 5% maltodextrin and an initial concentration of probiotics in the order of 4x1011 CFU, and an encapsulated Basillus clausii 3.53x1010 CFU / g is obtained, resistant to baking temperatures of 170 ° -210 °.

2. The encapsulated probiotic of claim 1, wherein the encapsulation of the microorganism is determined to be possible to change the microorganism to be encapsulated within the size range of those tested, this due to the size of the encapsulated microorganisms that ranged from circular spore-forming microorganisms (less than one micrometer) to bacilli (approximately 2 micrometers) with the formulations obtained.

3. The encapsulated probiotic of claim 1, wherein the formulation can be scaled to produce from 4 g to 150 g per run in spray drying equipment.

4. The encapsulated probiotic of claim 1, wherein the optimal dose for incorporation into bread is between 4g to 10g per 100g of the dry ingredients for making sliced ​​bread, to obtain a viability of between 1x106 and 1x108 for each microorganism.

5. The formulation of a probiotic stable at baking temperatures encapsulated for food, the formulation consists of: a probiotic Lactobacillus acidophilus 1.22x108 CFU / g is obtained by spray drying, in a probiotic Lactobacillus acidophilus with 30% Inulin, 40% pea protein, 25% maltodextrin and an initial concentration of probiotics in the order of 4x108 CFU resistant to baking temperatures of 170°-210°.

6. The encapsulated probiotic of claim 5, wherein the encapsulation of the microorganism is determined to be possible to change the microorganism to be encapsulated within the size range of those tested, this due to the size of the microorganisms. encapsulated cells ranging from circular spore-forming cells (smaller than one micrometer) to rod-shaped cells (approximately 2 micrometers) with the formulations obtained.

7. The encapsulated probiotic of claim 5, wherein the formulation can be scaled to produce from 4 g to 150 g per run in spray drying equipment.

8. The encapsulated probiotic of claim 5, wherein the optimal dose for incorporation into bread is between 4g to 10g per 100g of the dry ingredients for making sliced ​​bread, to obtain a viability of between 1x106 and 1x108 for each microorganism.

9. The encapsulated probiotic of claim 1 and 5, wherein the encapsulation consists of 2 probiotics containing Lactobacillus acidophilus in 6.69X108 CFU / g of encapsulation and Basilillus clausii in 2.24X1010 CFU / g of encapsulation.

Citation Information

Patent Citations

  • Thermo-stable strains, products and methods thereof

    US20170157184A1

  • Pro-healthy food product

    WO2015053641A1